Use of (pyrophosphato)platinum(II) or (pyrophosphato)platinum(IV) complexes (“phosphaplatin compounds”), especially (R,R)1,2-cyclohexanediamine-(dihydrogen pyrophosphato)platinum(II) (or “PT-112”), as therapeutic agents for treatment of bone and blood cancers, or cancers that metastasize to bones, and methods thereof, are disclosed.